.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,451,340

« Back to Dashboard
Patent 6,451,340 protects HEPSERA and is included in one NDA. There has been one Paragraph IV challenge on Hepsera.

This patent has fifty-six patent family members in twenty-five countries.

Summary for Patent: 6,451,340

Title: Nucleotide analog compositions
Abstract:The invention provides crystalline forms of adefovir dipivoxil and methods to prepare the crystals. The compositions and methods of the present invention have desirable properties for large scale synthesis of crystalline adefovir dipivoxil or for its formulation into therapeutic dosages. Invention compositions include an anhydrous crystal form of adefovir dipivoxil.
Inventor(s): Arimilli; Murty N. (Fremont, CA), Kelly; Daphne E. (San Francisco, CA), Lee; Thomas T. K. (Redwood City, CA), Manes; Lawrence V. (Moss Beach, CA), Munger, Jr.; John D. (Alviso, CA), Prisbe; Ernest J. (Los Altos, CA), Schultze; Lisa M. (San Carlos, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:09/950,031
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation; Process; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 8th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Gilead
HEPSERA
adefovir dipivoxil
TABLET;ORAL021449-001Sep 20, 2002RXYes6,451,340► subscribeYY THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,451,340

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina016548► subscribe
Austria228357► subscribe
Austria277936► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc